Filing Flows › Health Care › Guardant Health (GH)
Guardant Health (GH) earnings and revenue breakdown
Latest: Q3 2026 · 10-Q filed Nov 5, 2026 · Guardant Health (GH) Q3 2026 earnings results →
Q3 2026 Revenue up 36% year over year to $361M · 34¢ of every $1 of revenue lost · operating margin -36.8%
Guardant Health made $361M in Q3 2026 (+36% Y/Y): Oncology $231M, Screening $67.6M, Biopharma and data $59.0M. Operating margin -36.8%, net loss $124M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Nov 5, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $361.0M in Q3 2026, up 36% year over year and up 8% from the previous quarter. Oncology was the largest line at 64% of revenue. Oncology added $46.9M year over year (up 25%), 49% of the total change.
Operating costs exceeded revenue by $132.8M, an operating margin of -36.8%. Total costs grew 36% against revenue growth of 36%. The fastest-growing cost line was General & admin (+71%). The quarter ended with a net loss of $124.4M, wider than the previous quarter's $120.1M loss.
Operating cash flow was −$23.7M. Non-cash charges added back $10.2M of depreciation and amortization and $62.4M of share-based compensation. Working capital and other items added $28.0M. Capital expenditures of $13.5M exceeded it, leaving free cash flow of −$37.2M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q3 2026 | 10-Q | Nov 5, 2026 | $361M | +36% | -36.8% | −$124M | −$23.7M |
| Q2 2026 | 10-Q | Jul 30, 2026 | $335M | +44% | -38.5% | −$120M | −$57.8M |
| Q1 2026 | 10-Q | May 7, 2026 | $302M | +48% | -40.2% | −$112M | −$65.6M |
| Q4 2025 | 10-K | Feb 19, 2026 | $281M | +39% | -43.0% | −$128M | −$26.4M |
| Q3 2025 | 10-Q | Oct 29, 2025 | $265M | +38% | -37.3% | −$92.7M | −$35.4M |
| Q2 2025 | 10-Q | Jul 30, 2025 | $232M | +31% | -45.9% | −$99.9M | −$60.3M |
| Q1 2025 | 10-Q | Apr 30, 2025 | $203M | +21% | -54.6% | −$95.2M | −$62.7M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
Customers and suppliers named in filings
Buys from
About Guardant Health
We are a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. We are transforming patient care by providing critical insights into what drives disease through our advanced blood and tissue tests, real-world data and AI analytics. Our tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. For patients with advanced-stage cancer, we offer the Guardant360 Liquid test, formerly known as the Guardant360 LDT test, and the Guardant360 CDx test, the first comprehensive liquid biopsy test approved by the U.S.
In its own words, from its 10-K, filed Feb 19, 2026.
Guardant Health against its Services-Medical Laboratories peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +36% against the peers' median +15%. Operating margin: -36.8% against the peers' median 7.0%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| GH Guardant Health | Q3 2026 | $361M | +36% | -36.8% |
| LH Labcorp Holdings | Q3 2026 | $3.8B | +7% | 10.6% |
| DGX Quest Diagnostics | Q3 2026 | $3.1B | +10% | 15.5% |
| NTRA Natera | Q3 2026 | $794M | +34% | -8.6% |
| FTRE Fortrea Holdings | Q3 2026 | $692M | -1% | 2.2% |
| RDNT RadNet | Q2 2026 | $623M | +25% | 6.3% |
| CAI Caris Life Sciences | Q3 2026 | $275M | +27% | 7.0% |
| LMRI Lumexa Imaging Holdings | Q2 2026 | $264M | +5% | 8.7% |
| VCYT Veracyte | Q3 2026 | $152M | +15% | 10.9% |
Source: Guardant Health 10-Q on SEC EDGAR · CIK 1576280 · Services-Medical Laboratories
Guidance and outlook
13F: who owns GH and who is buying
More on GH
- How Guardant Health makes money: revenue by segment
- Guardant Health next earnings date and what analysts expect
- Guardant Health stock forecast, price target and fair value
- Who owns Guardant Health stock: holders, funds and Congress trades
- Guardant Health guidance and outlook
- Is Guardant Health a takeover target? LBO and rumors
History
Every quarter: Q3 2026 results · Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results